4.7 Review

Development of antiviral therapy for severe acute respiratory syndrome

Journal

ANTIVIRAL RESEARCH
Volume 66, Issue 2-3, Pages 81-97

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2005.03.002

Keywords

anti-viral therapy; SARS-CoV; ribavirin

Ask authors/readers for more resources

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing. (c) 2005 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available